JP7029213B2 - 新規な化合物およびこれを含む肥満または代謝症候群の予防または治療用薬学的組成物 - Google Patents

新規な化合物およびこれを含む肥満または代謝症候群の予防または治療用薬学的組成物 Download PDF

Info

Publication number
JP7029213B2
JP7029213B2 JP2021502678A JP2021502678A JP7029213B2 JP 7029213 B2 JP7029213 B2 JP 7029213B2 JP 2021502678 A JP2021502678 A JP 2021502678A JP 2021502678 A JP2021502678 A JP 2021502678A JP 7029213 B2 JP7029213 B2 JP 7029213B2
Authority
JP
Japan
Prior art keywords
compound
ethanol
obesity
present
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021502678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517171A5 (enExample
JP2021517171A (ja
Inventor
クォン，ヨン・テ
ガニピセッティ，スリニヴァスラオ
ソン，ギ・ウン
ジョン，ウィ・ジョン
ペ，テ・ヒョン
ムン，ス・ラン
ジョン，チャン・フン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protech Inc
Original Assignee
Protech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protech Inc filed Critical Protech Inc
Publication of JP2021517171A publication Critical patent/JP2021517171A/ja
Publication of JP2021517171A5 publication Critical patent/JP2021517171A5/ja
Application granted granted Critical
Publication of JP7029213B2 publication Critical patent/JP7029213B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/60—Preparation of compounds containing amino groups bound to a carbon skeleton by condensation or addition reactions, e.g. Mannich reaction, addition of ammonia or amines to alkenes or to alkynes or addition of compounds containing an active hydrogen atom to Schiff's bases, quinone imines, or aziranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021502678A 2018-03-26 2019-03-26 新規な化合物およびこれを含む肥満または代謝症候群の予防または治療用薬学的組成物 Active JP7029213B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648381P 2018-03-26 2018-03-26
US62/648,381 2018-03-26
PCT/KR2019/003514 WO2019190172A1 (ko) 2018-03-26 2019-03-26 신규한 화합물 및 이를 포함하는 비만 또는 대사증후군의 예방 또는 치료용 약학적 조성물

Publications (3)

Publication Number Publication Date
JP2021517171A JP2021517171A (ja) 2021-07-15
JP2021517171A5 JP2021517171A5 (enExample) 2021-08-26
JP7029213B2 true JP7029213B2 (ja) 2022-03-03

Family

ID=68060316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021502678A Active JP7029213B2 (ja) 2018-03-26 2019-03-26 新規な化合物およびこれを含む肥満または代謝症候群の予防または治療用薬学的組成物

Country Status (8)

Country Link
US (1) US12065394B2 (enExample)
EP (1) EP3778555A4 (enExample)
JP (1) JP7029213B2 (enExample)
KR (1) KR102054399B1 (enExample)
CN (1) CN112105598B (enExample)
AU (1) AU2019243133B2 (enExample)
TW (1) TWI717712B (enExample)
WO (1) WO2019190172A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768708A4 (en) 2018-03-23 2022-08-03 The Regents of the University of California METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY
AU2019312065A1 (en) 2018-07-24 2021-02-18 Protech Co., Ltd. Novel autophagy-targeting chimera (AUTOTAC) compound, and composition for preventing, alleviating, or treating diseases through target protein degradation comprising same
US12383624B2 (en) 2018-07-24 2025-08-12 Seoul National University R&Db Foundation Cargo delivery system and composition comprising the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022919A1 (en) 2011-08-08 2013-02-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor
WO2016200827A1 (en) 2015-06-11 2016-12-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor
WO2017030292A1 (ko) 2015-08-18 2017-02-23 서울대학교 산학협력단 P62 zz 도메인에 결합하는 리간드 또는 아르기닌화된 bip에 의해 매개되는 오토파지 활성을 통한 신경변성 질환 예방 및 치료

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0641766T3 (da) 1991-10-04 1999-07-26 Taisho Pharmaceutical Co Ltd Alkoxyphenylalkylaminderivat
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
JP3421702B2 (ja) * 1993-03-26 2003-06-30 大正製薬株式会社 シグマ受容体拮抗薬
US6451823B1 (en) 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
MX2009000714A (es) 2006-07-19 2009-07-27 Osurf Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos.
KR101594168B1 (ko) * 2013-10-02 2016-02-15 서울대학교산학협력단 p62의 ZZ 영역에 의해 매개되는 자가포식 조절 방법 및 그 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022919A1 (en) 2011-08-08 2013-02-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor
WO2016200827A1 (en) 2015-06-11 2016-12-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor
WO2017030292A1 (ko) 2015-08-18 2017-02-23 서울대학교 산학협력단 P62 zz 도메인에 결합하는 리간드 또는 아르기닌화된 bip에 의해 매개되는 오토파지 활성을 통한 신경변성 질환 예방 및 치료

Also Published As

Publication number Publication date
EP3778555A1 (en) 2021-02-17
AU2019243133A1 (en) 2020-10-08
EP3778555A4 (en) 2022-03-02
WO2019190172A1 (ko) 2019-10-03
CN112105598B (zh) 2023-06-27
TW201940461A (zh) 2019-10-16
AU2019243133B2 (en) 2021-03-04
CN112105598A (zh) 2020-12-18
KR20190112673A (ko) 2019-10-07
US20210024454A1 (en) 2021-01-28
US12065394B2 (en) 2024-08-20
KR102054399B1 (ko) 2019-12-10
JP2021517171A (ja) 2021-07-15
TWI717712B (zh) 2021-02-01

Similar Documents

Publication Publication Date Title
JP2022105149A (ja) 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用
US10738024B2 (en) Compounds for treatment of angiogenesis-mediated diseases
JP7029213B2 (ja) 新規な化合物およびこれを含む肥満または代謝症候群の予防または治療用薬学的組成物
WO2008144982A1 (en) Compounds with 7-member cycle and the pharmaceutical use thereof for preventing and treating diabetes and metabolism syndrome
JP2010525053A (ja) 新規なフェナントレンキノン系化合物およびそれを含むメタボリックシンドローム関連疾患を治療または予防するための医薬組成物
KR20230003981A (ko) DYRK1 억제제인 피롤로[3,2-c]피리딘 유도체 및 이의 용도
JP2021193149A (ja) 末梢セロトニンと関連する疾患または障害を処置するためのトリプトファンヒドロキシラーゼ１（ｔｐｈ１）の結晶性スピロ環式化合物インヒビター
JP5934839B2 (ja) ベルベノン誘導体を含有する退行性脳疾患治療または予防用薬学組成物
TW201904968A (zh) 以三唑并吡啶治療rbp4相關疾病之方法
JP2016506918A (ja) イソメテプテン異性体
HRP20040558A2 (en) Pharmaceutically effective compounds
CN114555577A (zh) 用于治疗门静脉炎症和纤维化的噻吩衍生物
JP5957452B2 (ja) 肝臓、肺の障害、糖尿病合併症および心血管疾患の処置のためのジフェニルエーテル化合物
CN110117302B (zh) 神经退行性疾病的治疗药物及其应用
WO2018015862A1 (en) 1-methylnicotinamide salts for use in raising the blood levels of adiponectin
KR102580387B1 (ko) 신규한 피라졸로[3,4-b]피리딘 유도체를 포함하는 비만 및 당뇨병을 비롯한 대사성질환 또는 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN120570882A (zh) 代谢功能障碍相关的脂肪性肝炎治疗药物
JP2010208996A (ja) 置換フェニルプロピオン酸誘導体を含有する医薬組成物
CN109608346B (zh) 查尔酮双曼尼希碱类化合物、其制备方法和用途
WO2023207460A1 (zh) 一种大麻二酚衍生物及其制备方法和应用
CN110240583A (zh) 一种苯并吡喃类化合物、及其制备方法和药物组合物与用途
CN120157625A (zh) 苯并-1,4-二氮杂卓-2,5-二酮类衍生物及其组合物、用途
WO2008089659A1 (fr) Utilisation de doubles inhibiteurs de transporteurs de dopamine et de transporteurs de noradrénaline

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220210

R150 Certificate of patent or registration of utility model

Ref document number: 7029213

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250